Close Menu
December 17, 2019
Sponsored by
Thermo Fisher Scientific

Non-Invasive Characterization of Solid Tumors via NGS Liquid Biopsy Testing

GenomeWebinar

Co-Director, Solid Tumor and Constitutional Disease Diagnostic Laboratory,
University of Navarra

This webinar reviews how liquid biopsy can be considered as an alternative and non-invasive method to tissue biopsy for cancer molecular characterization.

Liquid biopsy enables the study of tumor-specific circulating components, including circulating tumor cells (CTCs), circulating cell-free tumor DNA (ctDNA) and RNA (ctRNA). The approach brings both great potential and new challenges to precision medicine.

This webinar highlights two key aspects of successful implementation of liquid biopsy in the laboratory: proficiency testing and interlaboratory comparison. Additionally, our speaker, Dr. Gorka Alkorta-Aranburu of University of Navarra, discusses specifics of the liquid biopsy methodology, including properties of cell-free nucleic acids and considerations for next-generation sequencing technology.

Learning objectives:

  • The benefits of liquid biopsy as a non-invasive method to better understand cancer development and treatment.
  • The advantages (and challenges) of an NGS approach to study circulating cell-free nucleic acids for clinical applications.
Sponsored by

Novavax has begun a phase III trial of its SARS-CoV-2 vaccine, according to the New York Times.

Vox reports that the Trump Administration may limit student visas for individuals from some countries to two years.

The governor of New York says the state will conduct its own review of any SARS-CoV-2 vaccine, NPR reports.

This week in Science: Neanderthal Y chromosomes replaced by Homo sapiens Y chromosomes, and more.

Oct
06
Sponsored by
10x Genomics

Idiopathic pulmonary fibrosis (IPF) is a progressive and fatal lung disease characterized by irreversible scarring of the distal lung, leading to respiratory failure. 

Oct
14
Sponsored by
Inivata

Circulating tumor DNA (ctDNA) can allow clinicians and researchers to better understand which patients are at high risk of recurrence and should be offered intensified chemotherapy or selected for clinical trials.

Oct
20
Sponsored by
Stilla

This webinar will discuss a new method that relies on Crystal digital PCR from Stilla Technologies to monitor chimerism in patients after stem cell transplantation, which is a key part of surveillance for impending clinical relapse.

Oct
22
Sponsored by
Sophia Genetics

This webinar will share the Lorraine Cancer Institute's experience in implementing a novel targeted solution to accurately assess homologous recombination repair (HRR) deficiency by analyzing a series of genes, beyond BRCA, and calling multiple types of variants, including copy number variants (CNVs).